163 related articles for article (PubMed ID: 31253656)
1. The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs.
Rydenfelt M; Wongchenko M; Klinger B; Yan Y; Blüthgen N
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31253656
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
3. Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines.
Agioutantis PC; Loutrari H; Kolisis FN
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32517019
[TBL] [Abstract][Full Text] [Related]
4. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
[TBL] [Abstract][Full Text] [Related]
6. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
7. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
8. The proteomic landscape of triple-negative breast cancer.
Lawrence RT; Perez EM; Hernández D; Miller CP; Haas KM; Irie HY; Lee SI; Blau CA; Villén J
Cell Rep; 2015 Apr; 11(4):630-44. PubMed ID: 25892236
[TBL] [Abstract][Full Text] [Related]
9. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
Zecchin D; Boscaro V; Medico E; Barault L; Martini M; Arena S; Cancelliere C; Bartolini A; Crowley EH; Bardelli A; Gallicchio M; Di Nicolantonio F
Mol Cancer Ther; 2013 Dec; 12(12):2950-61. PubMed ID: 24107445
[TBL] [Abstract][Full Text] [Related]
12. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
[TBL] [Abstract][Full Text] [Related]
13. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
14. Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.
Sosman JA; Margolin KA
Curr Oncol Rep; 2009 Sep; 11(5):405-11. PubMed ID: 19679016
[TBL] [Abstract][Full Text] [Related]
15. Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers.
Béal J; Pantolini L; Noël V; Barillot E; Calzone L
PLoS Comput Biol; 2021 Jan; 17(1):e1007900. PubMed ID: 33507915
[TBL] [Abstract][Full Text] [Related]
16. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
18. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
19. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
[TBL] [Abstract][Full Text] [Related]
20. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Shi H; Moriceau G; Kong X; Lee MK; Lee H; Koya RC; Ng C; Chodon T; Scolyer RA; Dahlman KB; Sosman JA; Kefford RF; Long GV; Nelson SF; Ribas A; Lo RS
Nat Commun; 2012 Mar; 3():724. PubMed ID: 22395615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
